We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
IBA-Radcal

Download Mobile App




Green Laser Vaporizes Enlarged Prostates

By HospiMedica staff writers
Posted on 14 Jun 2006
A new surgical laser vaporizes enlarged prostates, providing rapid relief of urinary symptoms and a dramatic increase in urine flow. More...


The GreenLight HPS (High Performance System), made by Laserscope (San Jose, CA, USA), is a 532 nanometer wavelength green surgical laser designed to support the treatment of a range of soft tissue applications, including benign prostatic hyperplasia (BPH), bladder tumors, strictures, and lesions. Major benefits of the GreenLight HPS include a high power, low divergence laser beam allowing for precise and rapid tissue vaporization over a wide range of working distances, anatomy configurations, and tissue compositions; and a new delivery device design that eliminates backscatter, protecting vital tissue structures and providing higher efficiency vaporization.

Features include plug-and-play operation that auto-adjusts line voltage, an air cooled design and small form factor for use with standard utilities in a wide range of office and hospital settings, a voice-alert system, a touch-activated screen display that allows for easy adjustments of power and mode settings, as well as a number of pre-programmed settings for complete freedom during procedures.

The GreenLight HPS is an integral part of Laserscope's new GreenLight SurgiSuite, a solution designed to meet the needs of office-based surgical facilities for photo-selective vaporization (PVP) and other surgical procedures.

We are especially excited about the new GreenLight HPS, said Eric Reuter, president and CEO of Laserscope. "Customers wanted faster treatment speeds, better visibility, and for the product to operate using standard electrical service. We believe we have addressed these preferences and that this product will exceed customer expectations.

Half of all men over the age of 50 will develop BPH, a non-cancerous enlargement of the prostate that restricts urine flow. By the time men reach their 70s or 80s, 80% will experience urinary symptoms.


Related Links:
Laserscope

Gold Member
POC Blood Gas Analyzer
Stat Profile Prime Plus
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Absorbable Monofilament Mesh
Phasix Mesh
Open Stapler
PROXIMATE Linear Cutter
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Critical Care

view channel
Image: The researchers grew pancreatic tissue (above) so it incorporated a mesh-like electronic network (red). Cells within the tissue produce insulin (green). (Photo courtesy of Penn Medicine)

‘Cyborg’ Transplants Could Replace Pancreatic Tissue Damaged by Diabetes

Type 1 diabetes destroys insulin-producing islet cells, forcing patients to rely on lifelong insulin therapy or scarce organ transplants. Although lab-grown pancreatic tissue offers a promising alternative,... Read more

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.